tetano
Editor, Senior Moderator
Biol Blood Marrow Transplant. 2020 Apr 24. pii: S1083-8791(20)30229-9. doi: 10.1016/j.bbmt.2020.04.018. [Epub ahead of print]
Addressing the impact of the Coronavirus Disease (COVID-19) pandemic on hematopoietic cell transplantation: Learning networks as means for sharing best practices.
Ardura MI[SUP]1[/SUP], Hartley DM[SUP]2[/SUP], Dandoy C[SUP]3[/SUP], Lehmann L[SUP]4[/SUP], Jaglowski S[SUP]5[/SUP], Auletta JJ[SUP]6[/SUP]; Transplant-Associated Learning Network (TALNT).
Author information
Abstract
The full impact of the Coronavirus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus (SARS-CoV)-2 virus, on the field of hematopoietic cell transplantation (HCT) is unknown. This perspective paper reviews the following: current COVID-19 epidemiology, diagnosis and potential therapies; care considerations unique to HCT patients; and the concept of a learning network to assimilate emerging guidelines and best practices and to optimize patient outcomes through facilitating shared learning and experience across transplant centers.
Copyright ? 2020. Published by Elsevier Inc.
KEYWORDS:
COVID-19; SARS-CoV-2; bone marrow transplant; cell therapy; coronavirus; hematopoietic cell transplant; immunocompromised; severe acute respiratory syndrome
PMID:32339662DOI:10.1016/j.bbmt.2020.04.018
Addressing the impact of the Coronavirus Disease (COVID-19) pandemic on hematopoietic cell transplantation: Learning networks as means for sharing best practices.
Ardura MI[SUP]1[/SUP], Hartley DM[SUP]2[/SUP], Dandoy C[SUP]3[/SUP], Lehmann L[SUP]4[/SUP], Jaglowski S[SUP]5[/SUP], Auletta JJ[SUP]6[/SUP]; Transplant-Associated Learning Network (TALNT).
Author information
Abstract
The full impact of the Coronavirus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus (SARS-CoV)-2 virus, on the field of hematopoietic cell transplantation (HCT) is unknown. This perspective paper reviews the following: current COVID-19 epidemiology, diagnosis and potential therapies; care considerations unique to HCT patients; and the concept of a learning network to assimilate emerging guidelines and best practices and to optimize patient outcomes through facilitating shared learning and experience across transplant centers.
Copyright ? 2020. Published by Elsevier Inc.
KEYWORDS:
COVID-19; SARS-CoV-2; bone marrow transplant; cell therapy; coronavirus; hematopoietic cell transplant; immunocompromised; severe acute respiratory syndrome
PMID:32339662DOI:10.1016/j.bbmt.2020.04.018